Redmile’s $75M Sell‑Off of ADC Therapeutics Shares Signals Strategic Shift—What Investors and Clinicians Need to Know
Redmile Group’s $75M sell‑off of ADC Therapeutics shares highlights a strategic shift, while the firm’s promising TNBC ADC pipeline and Breakthrough Therapy status promise potential upside for investors and clinicians alike.
5 minutes to read